Advaxis Announces Two Abstracts Accepted for Presentation at SITC Annual Meeting

Advaxis Announces Two Abstracts Accepted for Presentation at SITC Annual Meeting

Advaxis, Inc.Diana Moore, 609-452-9814Director, Investor Relations & Business Development

., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts describing research with Advaxis -LLO immunotherapies have been selected for oral and poster presentations at the Society for Immunotherapy of Cancer (SITC) 27 Annual Meeting, October 26-28, 2012 at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, MD.

Abstract 1452783 titled “ADXS11-001 -LLO immunotherapy targeting HPV-E7: preliminary safety and survival data from a Phase 2 study in Indian women with recurrent/refractory cervical cancer” has been selected for oral presentation during the Combining Immunotherapy and Other Therapies session to be held on October 27, 2012 from 8:45 AM to 11:30 AM. Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis, will present updated safety and efficacy data from the ongoing trial.

Abstract 1452633 titled “Development of bivalent -LLO immunotherapy that concomitantly targets tumor cells and angiogenesis” has been selected for poster presentation at the Targeted Therapies and Anti-Tumor Immunity session to be held during the Annual Meeting. Dr. Anu Wallecha, Director of Research and Development at Advaxis, will report on the preclinical development of a bivalent -LLO immunotherapy using a novel strain of attenuated that delivers two antigen-adjuvant fusion proteins from a single bacterial vector. This construct targets two different antigens, one tumor-associated antigen and a non-specific antigen targeting the tumor’s blood supply.

“With the clinical data to be presented at SITC, Advaxis continues to demonstrate the utility of our novel technology for the treatment of cancer,” commented Dr. John Rothman, EVP of Science and Operations at Advaxis. “The commitment of Advaxis to develop new and potentially more versatile strains of to treat disease is exemplified by the work we will present on a bivalent -LLO vector.”

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.

In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the .

ADXS-HPV is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neckcancer (University of Liverpool/CRUK UK study, Clinical Trials.gov Identifier NCT0CT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the , , the , the , the , the , and others. For more information please visit: | |

.

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.